您好,欢迎光临世界标品! 登录 注册(订药物标准品请用邮件联系我们)

中国医药研发对照标品提供商
Non-clinical Research-used
Medicine Sample Provider

当前本网站药物产品种数共 7856 处方药 7487 非处方药 253 保健品/医疗用具 116

世界标品医药目录搜索(中英文):
世界各国官方药品目录搜索(英文):
世界标品医药知识搜索(中英文):

联系方式
国际免费电话:
QQ客服1:1793093587
QQ客服2:1586083059
QQ客服3:2786706041
QQ客服6:2992753224
QQ客服7:2394834588

咨询邮箱:
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com
投诉与建议:
complaint@shijiebiaopin.com

  药店国别: 德国药房
产地国家: 法国
所属类别: 抗癌药物->治疗肾癌药物
处方药:处方药
包装规格: 60毫克/片, 30片/盒
计价单位:
  点击放大  
生产厂家英文名:
Exelixis Pharma
该药品相关信息网址1:
https://www.cabometyxhcp.com/?utm_source=google&utm_medium=cpc&utm_term=cabometyx&utm_campaign=GS%2B-%2BBR%2B-%2B2018%2B-%2BBranded%2B-%2BHCP_GS%2B-%2BBrand%2BAlone_EX
该药品相关信息网址2:
https://www.rxlist.com/cabometyx-drug.htm
该药品相关信息网址3:
https://en.wikipedia.org/wiki/Cabozantinib
原产地英文商品名:
Cabometyx 60mg tablet, 30 tablets
原产地英文药品名:
cabozantinib
中文参考商品译名:
卡赞替尼片 60毫克/片, 30片
中文参考药品译名:
卡赞替尼
原产地国家批准上市年份:
0000/00/00
英文适应病症1:
Advanced renal cell carcinoma
临床试验期:
完成
中文适应病症参考翻译1:
晚期肾细胞癌
药品信息:

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(201892520375615.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------
部分CABOMETYX处方资料(仅供参考)

CABOMETYX™(卡赞替尼[cabozantinib])片,为口服使用

初始批准:2012 欧洲批准:2016年9月16日

作用机制

体外生化和/或细胞学分析曽显示卡赞替尼抑制MET,VEGFR-1,-2和-3,AXL,RET,ROS1,TYRO3,MER,KIT,TRKB,FLT-3,和TIE-2酪氨酸激酶的活性。这些受体酪氨酸激酶是涉及正常细胞学功能和病理学过程两个方面例如肿瘤发生,转移,肿瘤血管生成,药物抗性,和肿瘤慰环境的维持。

适应证和用途

CABOMETYX是一个激酶抑制剂适用为有晚期肾细胞癌(RCC)曽接受以前抗血管生成治疗患者的治疗。

剂量和给药方法

⑴ 推荐剂量:60mg口服,每天1次。 ⑵ 指导患者服用CABOMETYX前和后至少1小时不要吃共至少2小时。 ⑶ 不要用卡赞替尼胶囊替代CABOMETYX片。

剂型和规格

20mg,40mg,和60mg片。

禁忌证

无。

警告和注意事项

⑴ 出血:如最近严重出血病史不要给予CABOMETYX。

⑵ GI穿孔和瘘管:监视症状。对不能适当地处理或穿孔的瘘管终止。

⑶ 血栓性事件:对心肌梗死,脑梗塞,或其他严重动脉血栓栓塞事件终止CABOMETYX。

⑷高血压和高血压危象:定期地监视血压。对不能用抗高血压治疗控制高血压危象或严重高血压终止CABOMETYX。

⑸ 腹泻:可能是严重。立即中断CABOMETYX治疗直至腹泻解决或减轻至1级。推荐标准抗治疗。

⑹ 掌跖红感觉迟钝综合征(PPES):中断CABOMETYX治疗直至PPES解决或减轻至1级。

⑺ 可逆性后部白质脑病综合征(RPLS):终止CABOMETYX。

⑻ 胚胎-胎儿毒性:可致胎儿危害。忠告生殖潜能女性对胎儿潜在风险和使用有效避孕。

不良反应

最常报道的(≥ 25%)不良反应为:腹泻,疲乏,恶心,食欲减退,掌跖红感觉迟钝综合征(PPES),高血压,呕吐,体重减低,和便秘。

药物相互作用

强CYP3A4抑制剂:减低CABOMETYX剂量。

特殊人群中使用

⑴ 轻度至中度肝受损:减低CABOMETYX剂量。

⑵ 哺乳:当服用CABOMETYX时忠告不要哺乳喂养。

生产厂家:易普森公司 Ipsen Pharma

2016年2月29日,Exelixis和Ipsen联合宣布了一项独家许可协议,用于商业化和进一步开发美国,加拿大和日本以外的cabozantinib。

CABOMETYXTM (cabozantinib) tablets for oral use

Initial Approval: 2012 European Approval: September 16, 2016

Action mechanism

In vitro biochemical and/or cytological analysis showed that cazanidatin inhibits MET, VEGFR-1, -2 and -3, AXL, RET, ROS1, TYRO3, MER, KIT, TRKB, FLT-3, and TIE -2 tyrosine kinase activity. These receptor tyrosine kinases are involved in both normal cytological and pathological processes such as tumorigenesis, metastasis, tumor angiogenesis, drug resistance, and maintenance of the tumor comfort environment.

Indications and Uses

CABOMETYX is a kinase inhibitor suitable for the treatment of patients with advanced renal cell carcinoma (RCC) who have received previous anti-angiogenic therapy.

Dose and method of administration

(1) Recommended dose: 60mg orally, once a day. (2) Instruct patients to take at least 2 hours before and after taking CABOMETYX for at least 1 hour. (3) Do not replace CABOMETYX tablets with cazantinib capsules.

Formulations and specifications

20 mg, 40 mg, and 60 mg tablets.

Contraindications

no.

Warnings and Precautions

(1) Bleeding: Do not give CABOMETYX a history of severe bleeding.

(2) GI perforation and fistula: monitor symptoms. The fistula that is not properly treated or perforated is terminated.

(3) Thrombotic events: CABOMETYX is terminated for myocardial infarction, cerebral infarction, or other severe arterial thromboembolic events.

(4) Hypertension and hypertensive crisis: Regularly monitor blood pressure. CABOMETYX can be terminated by not being able to control hypertensive crisis or severe hypertension with antihypertensive therapy.

(5) Diarrhea: May be severe. Immediately discontinue CABOMETYX treatment until diarrhea is resolved or reduced to level 1. Recommended standard anti-treatment.

(6) Palmoplantar Red Syndrome Syndrome (PPES): discontinue CABOMETYX treatment until PPES resolves or reduces to grade 1.

(7) Reversible posterior leukoencephalopathy syndrome (RPLS): termination of CABOMETYX.

(8) Embryo-fetal toxicity: can cause fetal harm. Advise women with reproductive potential on potential risks to the fetus and use effective contraception.

Adverse reactions

The most frequently reported (≥ 25%) adverse reactions were: diarrhea, fatigue, nausea, loss of appetite, palmoplantar redness syndrome (PPES), hypertension, vomiting, weight loss, and constipation.

Drug interaction

Strong CYP3A4 inhibitor: Reduce the CABOMETYX dose.

Use

in special people

(1) Mild to moderate liver damage: Reduce the CABOMETYX dose.

(2) Breastfeeding: Do not breastfeed when taking CABOMETYX.

Manufacturer: Ipsen Pharma

February 29, 2016, Exelixis and Ipsen jointly announced an exclusive licensing agreement for the commercialization and further development of cabozantinib indications outside of the United States, Canada and Japan.

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(201892520375615.pdf)的“Prescribing Information”为准
---------------------------------------------------------------

更新日期: 2018-04-08
附件:
201892520375615.pdf    

 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间:太平洋时间18:00-24:00
国际免费电话:
友情提示:以上电话为免费电话,无需您承担任何费用,世界标品提供中文客服,请您放心拨打!
电子邮箱:info.shijiebiaopin.com@gmail.com, info@shijiebiaopin.com